Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma

Author: Antonini Giovanni   Cox Maria   Montefusco Enrico   Ferrari Antonella   Conte Esmeralda   Morino Stefania   Latino Pamela   Trasimeni Guido   Monarca Bruno  

Publisher: Springer Publishing Company

ISSN: 0167-594X

Source: Journal of Neuro-Oncology, Vol.81, Iss.2, 2007-01, pp. : 197-199

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

A patient with relapsed B cell non-Hodgkin lymphoma (NHL) infiltrating the Central nervous system (CNS) and resistant to chemotherapy was treated with intrathecal Rituximab (IT RTX), administered weekly for eight weeks at increasing doses, from 10 to 40 mg. After the second administration the patient showed significant clinical improvement and Cerebro spinal fluid (CSF) clearance of lymphomatous cells. A MRI scan performed after 30 days from the start of therapy showed full regression of lymphomatous infiltration. This report confirms the efficacy and safety of IT RTX in the treatment of CNS B-cell NHL.

Related content